Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
March 06, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference

NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
January 30, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)

NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
January 18, 2019 11:21 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Closes $92 Million Public Offering of Common Stock

NEW YORK, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
January 15, 2019 22:04 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock

NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
January 14, 2019 16:35 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
January 07, 2019 09:50 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Submission of European Marketing Authorization Application (MAA) for ELZONRIS™

NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...
January 02, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...
December 06, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Recaps Key Clinical Data Presentations from the American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
November 30, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting

NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right